comparemela.com

Latest Breaking News On - George clinical - Page 2 : comparemela.com

George Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical Trials

George Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical Trials
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states
France
Sydney
New-south-wales
Australia
New-york
French
Susan-cole
Societas-europaea
Prnewswire-medidata
Asia-pacific-at-medidata-solutions
Contract-research-organization-cros

Business News | George Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical Trials

Get latest articles and stories on Business at LatestLY. Sydney [Australia], November 14: Medidata, a Dassault Systemes company, announced today that George Clinical, a leading global clinical research organization, is leveraging Medidata's cloud-based clinical solution Rave Grants Manager. Through this partnership, George Clinical will be able to provide its global clients with a robust, data-driven approach to quickly and accurately develop investigator grant budgets, enhancing operational efficiency and patient recruitment. Additionally, Medidata will also be providing training to ensure seamless adoption and use of the software. Business News | George Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical Trials.

Sydney
New-south-wales
Australia
United-states
Simulia
West-bengal
India
France
New-york
French
Societas-europaea
Susan-cole

Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC

Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.

Hong-kong
Selpercatinib-retevmo
Eli-lilly
Merck-sereno
Guardant-health
Novartis
Poisons-committee
Pfizer
East-asian
Non-east-asia
East-asia
George-clinical

NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for treatment of pediatric attention deficit hyperactivity disorder (ADHD) as a monotherapy for patients ages 7 through 12 years old who are not currently taking prescrip

United-states
California
Singapore
Los-angeles
Colin-kealey
C-thomas-paschall
Singapore-health-sciences-authority
Checkmate-capital-group
Health-sciences-authority
Trigeminal-nerve-stimulation
Neurosigma-singapore
Southeast-asia

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.